liposomal T4N5 lotion

Phase 3Small molecule

NNational Cancer Institute (NCI)

liposomal T4N5 lotion is one of 31 small molecule programs targeting Kidney Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Xeroderma PigmentosumActive, not recruiting

Kidney TransplantPhase 2

Active, not recruiting

Xeroderma PigmentosumPhase 3

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Simulect

Novartis

Preclinical

15 3

Medrol

Pfizer

Preclinical

12 4

liposomal T4N5 lotion

NNational Cancer Institute (NCI)

Phase 3

1 5

Zinbryta

Roche

Preclinical

6 6

Sensipar

Amgen

Preclinical

1 7

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 8

Cysteine Hydrochloride

Novartis

Preclinical

1 9

Radicava

Shionogi

Preclinical

1 10

Jardiance

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Xeroderma Pigmentosum1 trial

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum

Unknown status·AApplied Genetics·Phase 3·NCT00002811·30 enrolled

Kidney Transplant1 trial

T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00089180·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for liposomal T4N5 lotion. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — liposomal T4N5 lotion compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for liposomal T4N5 lotion. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

liposomal T4N5 lotion

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Xeroderma Pigmentosum1 trial

Kidney Transplant1 trial

References

Drug Info

Quick Facts

Related News